Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Frailty × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Glioblastoma 136 Glioma 56 Brain Neoplasms 55 Gliosarcoma 42 Central Nervous System Neoplasms 42 Astrocytoma 34 Oligodendroglioma 27 Melanoma 25 Neuroblastoma 14 Sarcoma, Ewing 9 Sarcoma 9 Neuroendocrine Tumors 9 Neoplasm Metastasis 9 Medulloblastoma 9 Lung Neoplasms 8 Carcinoma, Non-Small-Cell Lung 8 Recurrence 7 Neoplasms 7 Ependymoma 7 Diffuse Intrinsic Pontine Glioma 7 Breast Neoplasms 7 Rhabdomyosarcoma 6 Ovarian Neoplasms 6 Lymphoma 6 Colorectal Neoplasms 5 Carcinoma, Neuroendocrine 5 Small Cell Lung Carcinoma 4 Pheochromocytoma 4 Adenoma, Islet Cell 4 Uveal Melanoma 3

Interventions

peflavit 1 microcrystalline cellulose 1 fisetin 1 epigallocatechin gallate 1 cabozantinib 1 Temozolomide 1 Quercetin 1 Protons 1 Photons 1 Flavonoids 1 Dasatinib 1 Ascorbic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05554003 2024-11-18

MeTe

European Institute of Oncology

Phase 2 Recruiting

Frailty, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡